Patents by Inventor Philippe Barthelemy

Philippe Barthelemy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10633409
    Abstract: The invention relates to bola-amphiphilic compounds and their uses for biomedical application. The invention particularly relates to the use of bola-amphiphilic compounds for providing low molecular weight gels (LMWG), useful, in particular, as culture media for animal or human cells, or as biocompatible material for biomedical applications.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: April 28, 2020
    Assignees: UNIVERSITE DE BORDEAUX, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Philippe Barthelemy, Michael Ramin, Laurent Latxague, Ananda Appavoo, Olivier Chassande, Camille Ehret
  • Patent number: 10633408
    Abstract: The invention relates to new nucleoside-lipid compounds with pH-sensitive dialkylorthoester chains, to the process for their preparation and to their uses, in particular their use for transportation or vectorization of at least one therapeutic agent.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: April 28, 2020
    Assignees: UNIVERSITE DE BORDEAUX, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Philippe Barthelemy, Khalid Oumzil
  • Patent number: 10343934
    Abstract: The present invention relates to the use of a supramolecular system in order to remove particles from a liquid medium containing same. According to the invention, the supramolecular system includes at least one molecule having a low molecular weight and/or an organic compound from living organisms, preferably from jellyfish, said compound being selected from among collagen, a polysaccharide, a proteoglycan or a mixture of two of said organic compounds, and said molecule having a low molecular weight and formula (I) as defined herein. The invention also relates to a method for removing particles from a liquid medium containing same. The invention is particularly suitable for use in water decontamination and biotechnology.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: July 9, 2019
    Assignee: UNIVERSITE DE BORDEAUX
    Inventors: Philippe Barthelemy, Alain Thiery, Amit Patwa
  • Patent number: 10227372
    Abstract: The invention relates to bola-amphiphilic compounds and their uses for biomedical application. The invention particularly relates to the use of bola-amphiphilic compounds for providing low molecular weight gels (LMWG), useful, in particular, as culture media for animal or human cells, or as biocompatible material for biomedical applications.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: March 12, 2019
    Assignees: UNIVERSITE DE BORDEAUX, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Philippe Barthelemy, Michael Ramin, Laurent Latxague, Ananda Appavoo, Olivier Chassande, Camille Ehret
  • Patent number: 9707250
    Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least three saturated or unsaturated, linear or branched hydrocarbon chains comprising from 2 to 30 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 18, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ DE BORDEAUX, Université d' Aix-Marseille, Institut Jean Paoli & Irene Calmettes, Centre Régional de Lutte Contre le Cancer, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S)
    Inventors: Philippe Barthelemy, Khalid Oumzil, Arnaud Gissot, Palma Rocchi, Julie Acunzo
  • Patent number: 9701962
    Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least one ketal functional group, wherein the ketal carbon of said ketal functional group bears two saturated or unsaturated, linear or branched, hydrocarbon chains comprising from 1 to 22 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 11, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE BORDEAUX, UNIVERSITE D 'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Philippe Barthelemy, Khalid Oumzil, Palma Rocchi, Julie Acunzo
  • Patent number: 9533049
    Abstract: The invention relates to a method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, optionally in the presence of at least one colipide, enabling the encapsulation of therapeutic agents, especially anti-tumoral agents, and the use thereof for the transport and vectorization of therapeutic agents, especially anti-tumoral agents.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 3, 2017
    Assignees: UNIVERSITE D'AIX-MARSEILLE, UNIVERSITE DE BORDEAUX, UNIVERSITÉ DE BOURGOGNE
    Inventors: Philippe Barthelemy, Michel Camplo, Nathalie Campins, Bruno Chauffert, Florence Bouyer
  • Publication number: 20160108398
    Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least one ketal functional group, wherein the ketal carbon of said ketal functional group bears two saturated or unsaturated, linear or branched, hydrocarbon chains comprising from 1 to 22 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.
    Type: Application
    Filed: June 5, 2014
    Publication date: April 21, 2016
    Inventors: Philippe Barthelemy, Khalid Oumzil, Palma Rocchi, Julie Acunzo
  • Patent number: 9050268
    Abstract: The invention relates to novel functional amphiphilic molecule or macromolecule formulations with multiple compartments for transporting or targeting at least one therapeutic agent, in particular an antitumor agent, as well as to a method for preparing such formulations and to the use thereof.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: June 9, 2015
    Assignees: UNIVERSITE d'AIX-MARSEILLE, UNIVERSITE DE BORDEAUX
    Inventors: Philippe Barthelemy, Salim Khiati, Michel Camplo
  • Publication number: 20150076062
    Abstract: The present invention relates to the use of a supramolecular system in order to remove particles from a liquid medium containing same. According to the invention, the supramolecular system includes at least one molecule having a low molecular weight and/or an organic compound from living organisms, preferably from jellyfish, said compound being selected from among collagen, a polysaccharide, a proteoglycan or a mixture of two of said organic compounds, and said molecule having a low molecular weight and formula (I) as defined herein. The invention also relates to a method for removing particles from a liquid medium containing same. The invention is particularly suitable for use in water decontamination and biotechnology.
    Type: Application
    Filed: January 25, 2013
    Publication date: March 19, 2015
    Inventors: Philippe Barthelemy, Alain Thiery, Amit Patwa
  • Publication number: 20120070505
    Abstract: The invention relates to novel functional amphiphilic molecule or macromolecule formulations with multiple compartments for transporting or targeting at least one therapeutic agent, in particular an antitumor agent, as well as to a method for preparing such formulations and to the use thereof.
    Type: Application
    Filed: May 28, 2010
    Publication date: March 22, 2012
    Applicants: UNIVERSITE DE LA MEDITERRANEE, UNIVERSITE BORDEAUX SEGALEN
    Inventors: Philippe Barthelemy, Salim Khiati, Michel Camplo
  • Publication number: 20110059180
    Abstract: The invention relates to a method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, optionally in the presence of at least one colipide, enabling the encapsulation of therapeutic agents, especially anti-tumoral agents, and the use thereof for the transport and vectorisation of therapeutic agents, especially anti-tumoral agents.
    Type: Application
    Filed: November 28, 2008
    Publication date: March 10, 2011
    Inventors: Philippe Barthelemy, Michel Camplo, Nathalie Campins, Bruno Chauffert, Florence Bouyer
  • Patent number: 7507859
    Abstract: The present invention describes a synthetic non-viral vector composition for gene therapy and the use of such compositions for in vitro, ex vivo and/or in vivo transfer of genetic material. The invention proposes a pharmaceutical composition containing 1) a non-cationic amphiphilic molecule or macromolecule and its use for delivery of nucleic acids or 2) a cationic amphiphilic molecule or macromolecule that transforms from a cationic entity to an anionic, neutral, or zwitterionic entity by a chemical, photochemical, or biological reaction and its use for delivery of nucleic acids. Moreover this invention describes the use of these non-viral vector compositions in conjunction with a surface to mediate the delivery of nucleic acids. An additional embodiment is the formation of a hydrogel with these compositions and the use of this hydrogel for the delivery of genetic material. A further embodiment of this invention is the use of a change in ionic strength for the delivery of genetic material.
    Type: Grant
    Filed: June 16, 2004
    Date of Patent: March 24, 2009
    Assignee: Fifth Base LLC
    Inventors: Mark W. Grinstaff, Philippe Barthelemy, Carla Prata, Louis Moreau
  • Publication number: 20060241071
    Abstract: The present invention describes a synthetic non-viral vector composition for gene therapy and the use of such compositions for in vitro, ex vivo and/or in vivo transfer of genetic material. The invention proposes a pharmaceutical composition containing 1) a non-cationic amphiphilic molecule or macromolecule and its use for delivery of nucleic acids or 2) a cationic amphiphilic molecule or macromolecule that transforms from a cationic entity to an anionic, neutral, or zwitterionic entity by a chemical, photochemical, or biological reaction and its use for delivery of nucleic acids. Moreover this invention describes the use of these non-viral vector compositions in conjunction with a surface to mediate the delivery of nucleic acids. An additional embodiment is the formation of a hydrogel with these compositions and the use of this hydrogel for the delivery of genetic material. A further embodiment of this invention is the use of a change in ionic strength for the delivery of genetic material.
    Type: Application
    Filed: June 16, 2004
    Publication date: October 26, 2006
    Inventors: Mark Grinstaff, Philippe Barthelemy, Carla Prata, Louis Moreau
  • Publication number: 20030170312
    Abstract: The invention concerns a method for coating solid particles with a thermofusible agent which consists in: fluidizing the solid particles in an ascending air movement in spiral rotation to obtain a homogeneous individualised distribution of the particles in the air fluidized bed, the temperature of the air fluidized bed being lower than the melting point of the thermofusible agent; spraying on the particles the melted thermofusible agent in the form of atomised droplets, said droplets being distributed in a spraying cone included in an air zone, whereof the temperature enables to maintain, throughout said spraying process, a temperature of the thermofusible agent substantially equal its melting point, the spraying being carried out in the same direction and tangentially to the movement followed by the solid particles; finally, after the coating process, cooling the resulting coated particles so as to solidify the thermofusible agent around the particles.
    Type: Application
    Filed: January 21, 2003
    Publication date: September 11, 2003
    Inventors: Hassan Benameur, Philippe Barthelemy
  • Publication number: 20030021844
    Abstract: The invention concerns a pellet for immediate release of an active substance to be ingested, said pellet comprising at least one active substance, a binding agent and a diluting agent, characterised in that said binding agent: comprises a mixture of glycerides subjected to polyglycolysis whereof the fatty acids comprise at least 8 carbon atoms; has a melting point not less than 37° C.; has a hydrophilic/lipophilic balance not less than 10, said binding agent being capable of enhancing the active substance bioavailability.
    Type: Application
    Filed: July 17, 2002
    Publication date: January 30, 2003
    Inventors: Philippe Barthelemy, Nabil Farah, Pascale Roussin
  • Publication number: 20020142037
    Abstract: The invention relates to a process for the manufacture of a pharmaceutical composition with modified release of active principle comprising at least one active principle, a lipid matrix agent composed of ester of alcohol with at least one fatty acid and at least one adjuvant.
    Type: Application
    Filed: February 1, 2002
    Publication date: October 3, 2002
    Inventors: Nabil Farah, Philippe Barthelemy, Joseph Joachim
  • Publication number: 20020059479
    Abstract: This invention relates to a programmable adapter device between a higher level communication protocol supported by a higher level equipment (30) and at least one lower level communication protocol supported by a lower level automation equipment (40). The device comprises an adapter (20) provided with a first memory (25) containing a conversion program (15) between the higher level protocol and a lower level protocol, downloadable from the higher level equipment (30) and that can be executed by the adapter (20), and provided with a second non-volatile memory (26) containing a resident driver program (16) in order to initialise communication with the higher level equipment (30). A memory area (17) is used as an intermediate buffer to manage asynchronism between protocols. The lower level connecting cable (14) is used to identify a complete or partial identifier of the lower level protocol.
    Type: Application
    Filed: November 9, 2001
    Publication date: May 16, 2002
    Inventors: Christian Hardy, Frederic Puig, Philippe Barthelemy
  • Patent number: 6375987
    Abstract: The invention relates to a process for the manufacture of a pharmaceutical composition with modified release of active principle comprising at least one active principle, a lipid matrix agent composed of ester of alcohol with at least one fatty acid and at least one adjuvant. This process is characterized in that: a powder composed of at least one component selected in the group comprising the active principle and the adjuvant, is mixed, while heating and fluidizing, in order to obtain individual grains; the said lipid matrix agent is liquefied separately under warm conditions; the said powder is then coated under warm conditions by spraying the said lipid matrix agent over the individual grains; finally, the temperature of the combined product is lowered in order to allow the lipid matrix agent to solidify.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: April 23, 2002
    Assignee: Gattefossé, S.A.
    Inventors: Nabil Farah, Philippe Bärthelemy, Joseph Joachim
  • Patent number: 6309665
    Abstract: The invention concerns a composition comprising a microemulsion forming system by contact with a hydrophilic phase brought, after ingestion, by the physiological fluid, said microemulsion forming system comprising: at least an active principle; a lipophilic phase; a surfactant (TA); a co-surfactant (CoTA). The invention is characterized in that said composition further comprises an inert polymeric matrix which cannot be ionised at physiological pH, dispersed in the microemulsion forming system before ingestion, said polymeric matrix being capable, after ingestion, of forming on contacting the physiological fluid, a gelled polymeric matrix enabling to release by diffusion, in continuous and prolonged manner the already micro-emulsified active principle.
    Type: Grant
    Filed: February 2, 2001
    Date of Patent: October 30, 2001
    Assignee: Gattefosse S.A.
    Inventors: Philippe Barthelemy, Hassan Benameur